Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
82%
Epidermal Growth Factor Receptor
37%
Chemotherapy
29%
Lung Cancer
28%
Progression Free Survival
26%
Overall Survival
25%
Carboplatin
24%
Gefitinib
21%
Paclitaxel
21%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Toxicity
20%
Neoplasm
16%
Erlotinib
16%
Osimertinib
15%
Platinum
14%
Pemetrexed
14%
Adverse Event
14%
Diseases
12%
Docetaxel
12%
Survival
12%
Afatinib
11%
Cisplatin
11%
Bevacizumab
10%
Anaplastic Lymphoma Kinase
9%
Protein Tyrosine Kinase Inhibitor
9%
Small Cell Lung Cancer
9%
Drug
8%
Pharmacokinetics
8%
Ligand
8%
Clinical Trial
7%
Disease Exacerbation
6%
Crizotinib
6%
Malignant Neoplasm
6%
Combination Therapy
6%
Durvalumab
6%
Nivolumab
6%
Echinoderm
5%
Microtubule Associated Protein
5%
Survivin
5%
Stomach Cancer
5%
Biological Marker
5%
Medicine and Dentistry
Patient
100%
Non Small Cell Lung Cancer
48%
Therapeutic Procedure
35%
Cells
29%
Lung Cancer
28%
Epidermal Growth Factor Receptor
23%
Overall Survival
20%
Combination Therapy
18%
Inpatient
18%
Progression Free Survival
18%
Neoplasm
16%
Programmed Cell Death
14%
Chemotherapy
13%
Analysis
12%
Carboplatin
12%
Pemetrexed
11%
Survival
11%
Paclitaxel
11%
Toxicity
10%
Immune Checkpoint Inhibitor
10%
Diseases
10%
Epidermal Growth Factor Receptor
10%
Gefitinib
9%
Platinum
9%
Ligand
9%
Small Cell Lung Cancer
9%
Specimen
7%
Bevacizumab
7%
Cisplatin
7%
Radiation Therapy
7%
Receptor Gene
7%
Osimertinib
7%
Anaplastic Lymphoma Kinase
6%
Idiopathic Pulmonary Fibrosis
6%
Hazard Ratio
6%
Plasma
6%
Interstitial Lung Disease
5%
Docetaxel
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
33%
Mutation
20%
Cancer Cell
12%
Gefitinib
8%
CD44
8%
Anaplastic Lymphoma Kinase
7%
Receptor Gene
6%
Apoptosis
6%
Receptor Tyrosine Kinase Inhibitors
6%
Protein
5%
Overall Survival
5%
Sample
5%
Progression Free Survival
5%